Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 75.8%

Neg 0% Neu 75.8% Pos 0%

Goldman Sachs analyst Andrea Newkirk reinstates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and announces $337 price target.